Nyrada (ASX:NYR)
We talked to James Bonnar, CEO of Nyrada (ASX: NYR), about the company’s remarkable NYR-B103 lead candidate and the great preclinical data showing the drug has both cardioprotective and neuroprotective properties.
A preclinical efficacy study in Traumatic Brain Injury is ongoing with with Walter Reed Army Institute of Research and the University of New South Wales, and a Phase 1a clinical trial will commence before 2024 is out.
Check out Pitt Street Research’s coverage of NYR HERE!
Looking for the Best ASX Life Sciences Stocks to invest in right now?
